This multicenter, prospective, observational study will evaluate the use in clinical practice and the efficacy and safety of Pegasys (peginterferon alfa-2a) in Chinese participants with HBeAg negative chronic hepatitis B. Participants receiving Pegasys according to the local label will be followed for the duration of their treatment and for one year after cessation of treatment.
Study Type
OBSERVATIONAL
Enrollment
978
Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling.
Incidence of sustained suppression of HBV DNA <2000 IU/mL one year after treatment cessation
Time frame: approximately 4 years
Incidence of suppression of HBV DNA <2000 IU/mL at the end of treatment and 6 months post-treatment
Time frame: approximately 4 years
Incidence of HBV DNA undetectable (<400 IU/mL) at the end of treatment and 1 year post-treatment
Time frame: approximately 4 years
Incidence of HBsAg loss/seroconversion
Time frame: approximately 4 years
Incidence of normalization of serum ALT levels
Time frame: approximately 4 years
Dosage/schedule of Pegasys treatment in real-life clinical setting
Time frame: approximately 4 years
Clinical/demographic patient characteristics at initiation of treatment
Time frame: approximately 4 years
Safety: Incidence of adverse events
Time frame: approximately 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Fifth Hospital of Shijiazhuang
Baoding, China
Beijing Ditan Hospital
Beijing, China
Beijing 302 Hospital; No. 2 Infectious Disease Section
Beijing, China
Beijing Friendship Hospital
Beijing, China
Beijing You An Hospital; Digestive Dept
Beijing, China
Peking University Third Hospital
Beijing, China
Beijing Union Hospital
Beijing, China
the First Hospital of Jilin University
Changchun, China
Jilin Hepatobiliary Hospital
Changchun, China
Peoples Hospital of Hunan Province
Changsha, China
...and 78 more locations